万瑜，西南交通大学生命科学与工程学院，四川省海外高层次留学人才。

2006-2010, 四川大学，华西药学院，学士

2010-2013, 四川大学，华西药学院，硕士 （孙逊教授）

2013-2017, 澳大利亚昆士兰大学，化学和分子生物科学学院，博士 （Istvan Toth教授）

2017-2024，西南交通大学生命科学与工程学院，讲师

2024- ，西南交通大学生命科学与工程学院，副教授

研究方向：

基因药物传递系统；靶向给药系统；药物新剂型、新制剂。

科研项目：

国家自然科学青年基金项目：构建改善肿瘤缺氧的氟碳化多肽 siRNA/ 化药共载体系及其抗肿瘤治疗

中央高校科技创新项目：肿瘤同源靶向性仿生纳米递药系统的构建及评价

医工结合培育专项：靶向 HSC 纳米载体的构建及治疗肝纤维化的研究

成都市科技局技术创新研发项目：基于选择性生物正交策略的荧光成像技术用于肝纤维化诊断研究。

欢迎报考硕士研究生药学专业，对药剂学方向感兴趣的同学联系、咨询。

欢迎SRTP、本科毕业论文（设计）以及对本研究领域感兴趣的同学交流、咨询！

联系方式：

电话：13096360802

Email: yu.wan@swjtu.edu.cn

地址：交大工业园区（交大路144号）C座407

论文:

14. Qiuyue Lai, Wenlong Li, Dandan Hu, Zhenqiu Huang, Mingyu Wu, Shun Feng, Yu Wan*. Hepatic Stellate Cell-Targeted Chemo-Gene Therapy for Liver Fibrosis Using Fluorinated Peptide-Lipid Hybrid Nanoparticles. Journal of Controlled Release, 2024, 376: 601-617.

13. Yu Wan*, Yifei Cao, Dandan Hu, Qiuyue Lai, Yumeng Liu, Yuan Chen, Mingyu Wu*, Shun Feng*. Biomimetic Cancer-Targeting Nanoplatform Boosting AIEgens-Based Photodynamic Therapy and Ferroptosis by Disrupting Redox-Homeostasis. ACS Biomaterials Science & Engineering, 2024, 5; 10(6): 3813–3824.

12. Yu Wan*, Yuhan Yang, Qiuyue Lai, Wangxia Wang, Mingyu Wu, Shun Feng. Fluorinated Cell-Penetrating Peptide for Co-Delivering siHIF-1α and Sorafenib to Enhance In Vitro Anti-Tumor Efficacy. Pharmaceutics. 2023, 15(12), 2789.

11. Yu Wan*, Wangxia Wang, Qiuyue Lai, Mingyu Wu, Shun Feng. Advances in cell-penetrating poly(disulfide)s for intracellular delivery of therapeutics. Drug Discovery Today. 2023, 103668. 

10. Zhen Shi^#, Yuhan Yang^#, Ziyang Guo, Shun Feng, Yu Wan*. A cathepsin B/GSH dual-responsive fluorinated peptide for effective siRNA delivery to cancer cells. Bioorganic Chemistry. 2023, 106485. 

9. Yifei Cao, Yuhan Yang, Shun Feng, Yu Wan*. Biomimetic Cancer Cell-coated Albumin Nanoparticles for Enhanced Colloidal Stability and Homotypic Targeting of Breast Cancer Cells. Journal of Drug Delivery Science and Technology. 2022, 75, 103698.

8. Yu Wan*, Mingyu Wu, Shun Feng. Fluorinated vectors for gene delivery. Expert Opinion on Drug Delivery. 2022, 19:11, 1435-1448.

7. Xuehong Yu, Yuhua Yue, Haizhu Shi, Kaiyan Xu, Chungu Zhang, Yu Wan*, Shun Feng*. Induced Apoptosis of B16-F10 cells and Diminished the Effect of Dacarbazine. Nutrition and cancer-an international journal. 2022. 

6. Yu Wan; Wei Dai; Reshma J.Nevagi; Istvan Toth; Peter M.Moyle ; Multifunctional peptide-li pid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells, Acta Biomaterialia, 2017, 59: 257-268.

5. Yu Wan; Peter M Moyle; Pei Z Gn; Istvan Toth ; Design and evaluation of a stearylated mul ticomponent peptide-siRNA nanocomplex for efficient cellular siRNA delivery, Nanomedicine, 2017, 12(4): 281-293.

4. Yu Wan; Peter M Moyle; Michelle P Christie; Istvan Toth ; Nanosized, peptide-based multic omponent DNA delivery systems: optimization of endosome escape activity, Nanomedicine, 2016, 11: 907-911.

3. Yu Wan; Pete M Moyle; Istvan Toth ; Endosome Escape Strategies for Improving the Efficacy of Oligonucleotide Delivery Systems, Current Medicinal Chemistry, 2015, 22: 3326-3346.

2. Jie Zheng#, Yu Wan#, Abdelbary Elhissi, Zhirong Zhang, Xun Sun. Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles. Pharmaceutical research, 2014, 31: 2220-2233.

1. Yu Wan, Jianfeng Han; Gerui Fan; Zhirong Zhang; Tao Gong; Xun Sun ; Enzyme-responsive lip osomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicit y, Biomaterials, 2013, 12(34): 3020-3030.

硕士研究生：

2019：石振

2020：曹逸菲，阳雨涵

2021：赖秋月，王旺霞

2022：李文龙，黄振秋，胡丹丹

2023：徐亚鹏，明晓琪

2024:   苟佳，朱红玲，齐锦秀

期待你的加入~~~

Dr Wan received a PhD (July 2017) from The University of Queensland (UQ) Australia, a Master of Pharmaceutics (June 2013) and a Bachelor of Pharmacy (June 2010) from West China School of Pharmacy Sichuan University. She currently works as a lecturer in the School of Life science and Engineering Southwest Jiaotong University (2017-current).

Dr Wan works in the fields of Pharmaceutics, investigating novel delivery systems for genes, small molecules and photosensitizers to improve the therapy efficacy for various diseases, such as cancer, liver fibrosis.

Specific current areas of interest are detailed below:

• 1. Tumor homotypic targeting biomimetic drug delivery nanosystems.

• 2. Perfluorocarbon modified non-viral gene vectors. 

• 3. aHSC-targeted drug delivery for the treatment of liver fibrosis.